Core Insights - The first edition of the "Commercial Health Insurance Innovative Drug Directory" has been implemented, which includes 19 innovative drugs with significant clinical value that exceed the payment capacity of basic medical insurance [2][4] - The directory aims to benefit participants of the "Hui Min Bao" insurance, particularly those with severe illnesses, by providing access to high-cost innovative treatments [2][6] - The successful integration of these innovative drugs into hospitals remains a challenge, as many hospitals have specific requirements and policies that may hinder the adoption of these high-value drugs [3][4] Group 1 - The "Commercial Health Insurance Innovative Drug Directory" includes drugs for critical areas such as cancer, rare diseases, neurodegenerative diseases, and metabolic disorders, filling gaps in the basic medical insurance directory [2][4] - CAR-T therapy is highlighted as a significant treatment option for difficult-to-treat blood cancers, potentially extending patient survival from six months to over five years, but its high cost limits accessibility [2][3] - The implementation of the directory's benefits for "Hui Min Bao" participants depends on the acceptance of innovative drugs by the insurance products and their availability in hospitals [2][5] Group 2 - The "three exclusions" policy allows drugs in the directory to be exempt from certain cost monitoring and payment frameworks, but it does not resolve the challenges of getting these drugs into hospitals [4][5] - Some "Hui Min Bao" products have begun to connect with the directory, offering increased reimbursement rates for drugs used during hospitalization, but this is contingent on the drugs being included in hospital treatment [4][6] - There is encouragement from local medical insurance bureaus for retail pharmacies to stock drugs from the directory, which could help address the challenges of hospital access for high-cost innovative drugs [5][7] Group 3 - The directory includes drugs that are also part of some "Hui Min Bao" special drug coverage, with varying reimbursement rates for pre-existing and non-pre-existing conditions [6][7] - Some "Hui Min Bao" products have increased reimbursement rates for pre-existing conditions to 35%, indicating a shift towards better coverage for these patients [7] - Local medical insurance bureaus are supporting the design of new products and adjustments in reimbursement methods to better meet patient medication needs and reduce financial burdens [7]

Core Viewpoint - The introduction of the first "Commercial Health Insurance Innovative Drug Directory" marks a significant step in expanding access to innovative drugs for patients, particularly those with severe illnesses, through commercial health insurance products like "Hui Min Bao" [3][4]. Group 1: Overview of the Innovative Drug Directory - The first edition of the Commercial Health Insurance Innovative Drug Directory includes 19 innovative drugs that have significant clinical value but exceed the payment capacity of basic medical insurance [3]. - These drugs cover critical areas such as oncology, rare diseases, neurodegenerative diseases, and metabolic disorders, including CAR-T therapies and treatments for Alzheimer's disease [3]. Group 2: Benefits and Challenges for Patients - Patients with severe conditions, such as blood cancers, can benefit from CAR-T therapies, which can extend survival rates significantly, but the high costs have limited their accessibility [3]. - The actual benefits for "Hui Min Bao" participants depend on the integration of these innovative drugs into hospital treatment protocols and the specific commercial insurance product designs [4][5]. Group 3: Implementation and Hospital Integration - There are obstacles in the hospital integration of high-value innovative drugs, as hospitals face restrictions related to drug usage and operational costs [4]. - Some hospitals are in the process of applying for the inclusion of these drugs, but the success of this integration remains uncertain [4][5]. Group 4: Insurance Product Design and Coverage - Certain "Hui Min Bao" products have begun to align with the Commercial Health Insurance Innovative Drug Directory, offering increased reimbursement rates for drugs used during hospitalization [5]. - However, if the innovative drugs do not successfully enter hospital treatment, patients may not receive the intended reimbursement benefits [5][6]. Group 5: Future Directions and Support from Regulatory Bodies - Local health insurance bureaus are encouraging the integration of the innovative drug directory into retail pharmacies, which could help address the challenges of hospital access [6][7]. - There is a push for commercial insurance companies to design new products and adjust reimbursement methods to better meet patient needs and reduce their financial burden [7].